Promiximab
Promiximab is a humanized anti-CD56 IgG1 monoclonal antibody with a Kd value of 0.78 pM against the human target. Promiximab specifically binds to CD56-positive small cell lung cancer (SCLC) cells, possesses antiproliferative activity, and induces tumor regression. Promiximab serves as the antibody component of the antibody-drug conjugates Promiximab-DUBA and Promiximab-MMAE. Promiximab can be used in studies related to small cell lung cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2924882-34-6
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H526 | IC50 |
> 300 nM
|
Inhibition of cell viability against human NCI-H526 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
Inhibition of cell viability against human NCI-H526 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
|
29435172 |
| NCI-H524 | IC50 |
> 300 nM
|
Inhibition of cell viability against human NCI-H524 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
Inhibition of cell viability against human NCI-H524 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
|
29435172 |
| NCI-H69 | IC50 |
> 300 nM
|
Inhibition of cell viability against human NCI-H69 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
Inhibition of cell viability against human NCI-H69 small cell lung cancer cells assessed by CCK-8 assay after 72 hrs exposure.
|
29435172 |
In Vitro
Promiximab (0.02-1200 nM; 72 h) does not inhibit the viability of CD56-expressing small cell lung cancer (SCLC) cell lines NCI-H526, NCI-H524, NCI-H69, or human NK cells at concentrations up to 1200 nM[1].
Promiximab (1 μg/mL; 30 min) specifically binds to CD56-expressing small cell lung cancer (SCLC) cell lines NCI-H526, NCI-H524 and NCI-H69, but does not bind to CD56-negative SCLC cell lines NCI-H446 and NCI-H128[1].
Promiximab (1 μg/mL; 4 h) binds to both glycosylated and deglycosylated CD56 ECD, and cross-reacts with human CD56-expressing cells[1].
Promiximab (10 μg/mL; 30 min, 3 h) is efficiently internalized into CD56-expressing small cell lung cancer (SCLC) cell lines NCI-H526, NCI-H524 and NCI-H69[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SCLC cell lines NCI-H526, NCI-H524, NCI-H69, human NK cells
-
Concentration:0.02, 0.07, 0.29, 1.17, 4.69, 18.75, 75, 300, 1200 nM
-
Incubation Time:72 h
-
Result:Showed no significant inhibitory effect on cell viability.
In Vivo
Promiximab (5-10 mg/kg; i.v.; every three days; 3 total doses) causes no visible histopathological toxicity to major organs in Balb/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (female, 5-6 weeks old, subcutaneous xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; every three days; 3 total doses
-
Result:Allowed tumors to grow to approximately 2000 mm3 over the study period.
Maintained stable body weight throughout treatment.
-
Animal Model:Balb/c[1]
-
Dosage:5, 10 mg/kg
-
Administration:i.v.; every three days; 3 total doses
-
Result:Showed no obvious histopathological changes in heart, liver, spleen, lung, and kidney tissues compared to vehicle-treated controls.
Chemical Information
-
CAS No. 2924882-34-6
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Promiximab Related Classifications
HY-P992523 Related Classifications
Powered by Bioz